Bayhill Company Description
Bayhill Therapeutics wants to make it all better. The clinical-stage biopharmaceutical company develops products to treat autoimmune diseases. Its various product candidates are designed to restore the immune system to its normal state, known as "tolerance." Lead product candidate BHT-3009, for the treatment of multiple sclerosis, has completed proof-of-concept studies and will enter its next clinical trial during 2008. The company's second and third product candidates BHT-3021 and BHT-3034 are for the treatment of type 1 diabetes and myasthenia gravis, respectively. None of Bayhill's products have been approved for commercial sale. The company filed to go public in January 2008.
View the Comprehensive Company Description for Bayhill
The Company Description provides a historical perspective of Bayhill's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Bayhill's evolution in the marketplace.
